SEARCH

SEARCH BY CITATION

References

  • 1
    National Institutes of Health. Symptom Management in Cancer: Pain, Depression, and Fatigue. Bethesda, MD: National Institutes of Health; 2002. Available at: http://consensus.nih.gov/2002/2002CancerpaINDepressionFatiguesos022main.htm. Accessed November 1, 2010.
  • 2
    van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007; 18: 1437-1449.
  • 3
    American Pain Society (APS). Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. 6th ed. Glenview, IL: American Pain Society; 2008.
  • 4
    National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology for Adult Cancer Pain. V. 1.2010. Fort Washington, PA: National Comprehensive Cancer Network; 2010. Available at: www.nccn.org. Accessed November 1, 2010.
  • 5
    Sun V, Borneman T, Piper B, Koczywas M, Ferrell B. Barriers to pain assessment and management in cancer survivorship. J Cancer Surviv. 2008; 2: 65-71.
  • 6
    Brescia FJ. Palliative care in pancreatic cancer. Cancer Control. 2004; 11: 39-45.
  • 7
    Burton AW, Fanciullo GJ, Beasley RD, Fisch MJ. Chronic pain in the cancer survivor: a new frontier. Pain Med. 2007; 8: 189-198.
  • 8
    Cohen MZ, Easley MK, Ellis C, et al. Cancer pain management and the JCAHO's pain standards: an institutional challenge. J Pain Symptom Manage. 2003; 25: 519-527.
  • 9
    Gordon DB, Pellino TA, Miaskowski C, et al. A 10-year review of quality improvement monitoring in pain management: recommendations for standardized outcome measures. Pain Manag Nurs. 2002; 3: 116-130.
  • 10
    World Health Organization. Access to Controlled Medications Programme: Framework. Geneva, Switzerland: World Health Organization; 2007. Available at: http://www.who.int/medicines/areas/quality_safety/Framework_ACMP_withcover.pdf. Accessed November 2, 2010.
  • 11
    Breivik H, Cherny N, Collett B, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009; 20: 1420-1433.
  • 12
    Agency for Health Care Policy and Research. Clinical Practice Guideline for Cancer Pain Management. Rockville, MD: US Department of Health and Human Services; 1994.
  • 13
    Cleeland CS. The impact of pain on the patient with cancer. Cancer. 1984; 54( 11 suppl): 2635-2641.
  • 14
    Duggleby W. Enduring suffering: a grounded theory analysis of the pain experience of elderly hospice patients with cancer. Oncol Nurs Forum. 2000; 27: 825-831.
  • 15
    Miaskowski C, Dodd MJ, West C, et al. Lack of adherence with the analgesic regimen: a significant barrier to effective cancer pain management. J Clin Oncol. 2001; 19: 4275-4279.
  • 16
    Pargeon KL, Hailey BJ. Barriers to effective cancer pain management: a review of the literature. J Pain Symptom Manage. 1999; 18: 358-368.
  • 17
    Potter VT, Wiseman CE, Dunn SM, Boyle FM. Patient barriers to optimal cancer pain control. Psychooncology. 2003; 12: 153-160.
  • 18
    Ward S, Hughes S, Donovan H, Serlin RC. Patient education in pain control. Support Care Cancer. 2001; 9: 148-155.
  • 19
    Ward SE, Carlson-Dakes K, Hughes SH, Kwekkeboom KL, Donovan HS. The impact on quality of life of patient-related barriers to pain management. Res Nurs Health. 1998; 21: 405-413.
  • 20
    Ward SE, Goldberg N, Miller-McCauley V, et al. Patient-related barriers to management of cancer pain. Pain. 1993; 52: 319-324.
  • 21
    Miaskowski C, Dodd M, West C, et al. Randomized clinical trial of the effectiveness of a self-care intervention to improve cancer pain management. J Clin Oncol. 2004; 22: 1713-1720.
  • 22
    West CM, Dodd MJ, Paul SM, et al. The PRO-SELF(c): Pain Control Program—an effective approach for cancer pain management. Oncol Nurs Forum. 2003; 30: 65-73.
  • 23
    Ferrell BR, Rhiner M, Ferrell BA. Development and implementation of a pain education program. Cancer. 1993; 72( 11 suppl): 3426-3432.
  • 24
    Ward S, Donovan HS, Owen B, Grosen E, Serlin R. An individualized intervention to overcome patient-related barriers to pain management in women with gynecologic cancers. Res Nurs Health. 2000; 23: 393-405.
  • 25
    Ferrell BR, Grant M, Ritchey KJ, Ropchan R, Rivera LM. The pain resource nurse training program: a unique approach to pain management. J Pain Symptom Manage. 1993; 8: 549-556.
  • 26
    McCaffery M, Ferrell B, O'Neil-Page E, Lester M, Ferrell B. Nurses' knowledge of opioid analgesic drugs and psychological dependence. Cancer Nurs. 1990; 13: 21-27.
  • 27
    McCaffery M, Ferrell BR, Pasero C. Nurses' personal opinions about patients' pain and their effect on recorded assessments and titration of opioid doses. Pain Manag Nurs. 2000; 1: 79-87.
  • 28
    Elliott TE, Elliott BA. Physician attitudes and beliefs about use of morphine for cancer pain. J Pain Symptom Manage. 1992; 7: 141-148.
  • 29
    Elliott TE, Murray DM, Elliott BA, et al. Physician knowledge and attitudes about cancer pain management: a survey from the Minnesota cancer pain project. J Pain Symptom Manage. 1995; 10: 494-504.
  • 30
    Ferrell B, Virani R, Grant M, Vallerand A, McCaffery M. Analysis of pain content in nursing textbooks. J Pain Symptom Manage. 2000; 19: 216-228.
  • 31
    Rabow MW, Hardie GE, Fair JM, McPhee SJ. End-of-life care content in 50 textbooks from multiple specialties. JAMA. 2000; 283: 771-778.
  • 32
    Gee RE, Fins JJ. Barriers to pain and symptom management, opioids, health policy, and drug benefits. J Pain Symptom Manage. 2003; 25: 101-103.
  • 33
    National Institutes of Health. Symptom Management in Cancer: Pain, Depression, and Fatigue. Bethesda, MD: National Institutes of Health; 2002. Available at: http://consensus.nih.gov/2002/2002CancerpaINDepressionFatiguesos022main.htm. Accessed November 2, 2010.
  • 34
    Ezenwa MO, Ameringer S, Ward SE, Serlin RC. Racial and ethnic disparities in pain management in the United States. J Nurs Scholarsh. 2006; 38: 225-233.
  • 35
    Green CR, Anderson KO, Baker TA, et al. The unequal burden of pain: confronting racial and ethnic disparities in pain. Pain Med. 2003; 4: 277-294.
  • 36
    Sun VC, Borneman T, Ferrell B, Piper B, Koczywas M, Choi K. Overcoming barriers to cancer pain management: an institutional change model. J Pain Symptom Manage. 2007; 34: 359-369.
  • 37
    Borneman T, Piper BF, Sun VC, Koczywas M, Uman G, Ferrell B. Implementing the Fatigue Guidelines at one NCCN member institution: process and outcomes. J Natl Compr Canc Netw. 2007; 5: 1092-1101.
  • 38
    Borneman T, Koczywas M, Sun VC, Piper BF, Uman G, Ferrell B. Reducing patient barriers to pain and fatigue management. J Pain Symptom Manage. 2010; 39: 486-501.
  • 39
    Borneman T, Koczywas M, Sun V, et al. Effectiveness of a clinical intervention to eliminate barriers to pain and fatigue management in oncology. J Palliat Med. 2011; 14: 197-205.
  • 40
    American Pain Society (APS). Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. 5th ed. Glenview, IL: American Pain Society; 2003.
  • 41
    National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Distress Management.V. 1.2010. Fort Washington, PA: National Comprehensive Cancer Network; 2010. Available at: www.nccn.org. Accessed November 2, 2010.
  • 42
    Puchalski C, Ferrell B, Virani R, et al. Improving the quality of spiritual care as a dimension of palliative care: the report of the Consensus Conference. J Palliat Med. 2009; 12: 885-904.
  • 43
    Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev. 2002;( 2): CD002068.
  • 44
    Pasero C, McCaffery M. Pain Assessment and Pharmacological Management. New York, NY: Mosby Elsevier; 2011.
  • 45
    City of Hope Pain Resource Center (PRC). Available at: http://prc.coh.org. Accessed November 2, 2010.
  • 46
    Fink R, Gates R. Pain assessment. In: FerrellBR, CoyleN, eds. Oxford Textbook of Palliative Nursing. 3rd ed. New York, NY: Oxford University Press; 2010: 137-160.
  • 47
    Breitbart W, Kissane D, Chochinov HM. Dignity, meaning and demoralization: emerging paradigms in end of life care. In: ChochinovHM, BreitbartW, eds. Handbook of Psychiatry in Palliative Medicine. New York, NY: Oxford University Press; 2009: 324-340.
  • 48
    American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009; 57: 1331-1346.
  • 49
    Israel FJ, Parker G, Charles M, Reymond L. Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high-dose strong opioids: a randomized, double-blind, placebo-controlled, crossover trial. J Pain Symptom Manage. 2010; 39: 548-554.
  • 50
    Ridruejo E, Cacchione R, Villamil AG, Marciano S, Gadano AC, Mando OG. Imatinib-induced fatal acute liver failure. World J Gastroenterol. 2007; 13: 6608-6611.
  • 51
    Swarm R, Abernethy AP, Anghelescu DL, et al. Adult cancer pain. J Natl Compr Canc Netw. 2010; 8: 1046-1086.
  • 52
    Rainsford KD. Anti-inflammatory drugs in the 21st century. Subcell Biochem. 2007; 42: 3-27.
  • 53
    Shi S, Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol. 2008; 64: 233-252.
  • 54
    Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2008; 103: 2890-2907.
    Direct Link:
  • 55
    Juni P, Dieppe P, Egger M. Risk of myocardial infarction associated with selective COX-2 inhibitors: questions remain. Arch Intern Med. 2002; 162: 2639-2640; author reply 2640-2642.
  • 56
    Kerr DJ, Dunn JA, Langman MJ, et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med. 2007; 357: 360-369.
  • 57
    Scott PA, Kingsley GH, Smith CM, Choy EH, Scott DL. Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis. 2007; 66: 1296-1304.
  • 58
    McNicol E, Strassels SA, Goudas L, Lau J, Carr DB. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev. 2005;( 1): CD005180.
  • 59
    Schlansky B, Hwang JH. Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy. J Gastroenterol. 2009; 44( suppl 19): 44-52.
  • 60
    Muriel C, Failde I, Mico JA, Neira M, Sanchez-Magro I. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study. Clin Ther. 2005; 27: 451-462.
  • 61
    Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2003; 25: 150-168.
  • 62
    Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage. 2005; 29: 297-326.
  • 63
    Mercadante S, Villari P, Ferrera P, et al. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manage. 2006; 32: 175-179.
  • 64
    Pergolizzi JV Jr, Mercadante S, Echaburu AV, et al. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr Med Res Opin. 2009; 25: 1517-1528.
  • 65
    Srinivasan V, Wielbo D, Tebbett IR. Analgesic effects of codeine-6-glucuronide after intravenous administration. Eur J Pain. 1997; 1: 185-190.
  • 66
    Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007; 7: 257-265.
  • 67
    Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004; 351: 2827-2831.
  • 68
    Koren G, Cairns J, Chitayat D, Gaedigk A, Feeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet. 2006; 368: 704.
  • 69
    Sathyan G, Jaskowiak J, Evashenk M, Gupta S. Characterisation of the pharmacokinetics of the fentanyl HCl patient-controlled transdermal system (PCTS): effect of current magnitude and multiple-day dosing and comparison with IV fentanyl administration. Clin Pharmacokinet. 2005; 44( suppl 1): 7-15.
  • 70
    Mystakidou K, Katsouda E, Tsilika E, Parpa E, Vlahos L. Transdermal therapeutic fentanyl-system (TTS-F). In Vivo. 2004; 18: 633-642.
  • 71
    Shibutani K, Inchiosa MA Jr, Sawada K, Bairamian M. Pharmacokinetic mass of fentanyl for postoperative analgesia in lean and obese patients. Br J Anaesth. 2005; 95: 377-383.
  • 72
    Heiskanen T, Matzke S, Haakana S, Gergov M, Vuori E, Kalso E. Transdermal fentanyl in cachectic cancer patients. Pain. 2009; 144: 218-222.
  • 73
    Cone EJ, Heit HA, Caplan YH, Gourlay D. Evidence of morphine metabolism to hydromorphone in pain patients chronically treated with morphine. J Anal Toxicol. 2006; 30: 1-5.
  • 74
    Hutchinson MR, Menelaou A, Foster DJR, Coller JK, Somogyi AA. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004; 57: 287-297.
  • 75
    Murray A, Hagen NA. Hydromorphone. J Pain Symptom Manage. 2005; 29( 5 suppl): S57-S66.
  • 76
    Goforth HW. Hydromorphone-OROS formulation. Expert Opin Pharmacother. 2010; 11: 1207-1214.
  • 77
    Lotsch J. Opioid metabolites. J Pain Symptom Manage. 2005; 29( 5 suppl): S10-S24.
  • 78
    Finn J, Wright J, Fong J, et al. A randomised crossover trial of patient controlled intranasal fentanyl and oral morphine for procedural wound care in adult patients with burns. Burns. 2004; 30: 262-268.
  • 79
    Thwaites D, McCann S, Broderick P. Hydromorphone neuroexcitation. J Palliat Med. 2004; 7: 545-550.
  • 80
    Golf M, Paice JA, Feulner E, O'Leary C, Marcotte S, Mulcahy M. Refractory status epilepticus. J Palliat Med. 2004; 7: 85-88.
  • 81
    Wright AW, Mather LE, Smith MT. Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci. 2001; 69: 409-420.
  • 82
    Niscola P, Scaramucci L, Vischini G, et al. The use of major analgesics in patients with renal dysfunction. Curr Drug Targets. 2010; 11: 752-758.
  • 83
    Davis MP, Walsh D. Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer. 2001; 9: 73-83.
  • 84
    Morley JS, Bridson J, Nash TP, Miles JB, White S, Makin MK. Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomized controlled crossover trial. Palliat Med. 2003; 17: 576-587.
  • 85
    Nicholson AB. Methadone for cancer pain. Cochrane Database Syst Rev. 2007;( 4): CD003971.
  • 86
    Bruera E, Palmer JL, Bosnjak S, et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol. 2004; 22: 185-192.
  • 87
    Dale O, Sheffels P, Kharasch ED. Bioavailabilities of rectal and oral methadone in healthy subjects. Br J Clin Pharmacol. 2004; 58: 156-162.
  • 88
    Mercadante S, Porzio G, Ferrera P, et al. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain. 2008; 12: 1040-1046.
  • 89
    Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001; 84: 587-593.
  • 90
    Watanabe S, Tarumi Y, Oneschuk D, Lawlor P. Opioid rotation to methadone: proceed with caution. J Clin Oncol. 2002; 20: 2409-2410.
  • 91
    Mercadante S, Casuccio A, Fulfaro F, et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol. 2001; 19: 2898-2904.
  • 92
    Moryl N, Santiago-Palma J, Kornick C, et al. Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain. Pain. 2002; 96: 325-328.
  • 93
    Parsons HA, de la Cruz M, El Osta B, et al. Methadone initiation and rotation in the outpatient setting for patients with cancer pain. Cancer. 2010; 116: 520-528.
  • 94
    Benmebarek M, Devaud C, Gex-Fabry M, et al. Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone. Clin Pharmacol Ther. 2004; 76: 55-63.
  • 95
    Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004; 76: 250-269.
  • 96
    Wang JS, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos. 2003; 31: 742-747.
  • 97
    Bernard SA, Bruera E. Drug interactions in palliative care. J Clin Oncol. 2000; 18: 1780-1799.
  • 98
    Kornick CA, Kilborn MJ, Santiago-Palma J, et al. QTc interval prolongation associated with intravenous methadone. Pain. 2003; 105: 499-506.
  • 99
    Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy. 2003; 23: 802-805.
  • 100
    Cruciani RA, Sekine R, Homel P, et al. Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manage. 2005; 29: 385-391.
  • 101
    Reddy S, Fisch M, Bruera E. Oral methadone for cancer pain: no indication of Q-T interval prolongation or torsades de pointes. J Pain Symptom Manage. 2004; 28: 301-303.
  • 102
    Reddy S, Hui D, El Osta B, et al. The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study. J Palliat Med. 2010; 13: 33-38.
  • 103
    Doverty M, Somogyi AA, White JM, et al. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain. 2001; 93: 155-163.
  • 104
    Peles E, Schreiber S, Gordon J, Adelson M. Significantly higher methadone dose for methadone maintenance treatment (MMT) patients with chronic pain. Pain. 2005; 113: 340-346.
  • 105
    Mercadante S. Intravenous morphine for management of cancer pain. Lancet Oncol. 2010; 11: 484-489.
  • 106
    Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol. 2000; 27: 524-528.
  • 107
    Andersen G, Jensen NH, Christrup L, Hansen SH, Sjogren P. Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine. Palliat Med. 2002; 16: 107-114.
  • 108
    Davis MP, Varga J, Dickerson D, Walsh D, LeGrand SB, Lagman R. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer. 2003; 11: 84-92.
  • 109
    Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E. Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007; 9: 298-307.
  • 110
    Biancofiore G. Oxycodone controlled release in cancer pain management. Ther Clin Risk Manag. 2006; 2: 229-234.
  • 111
    Lauretti GR, Oliveira GM, Pereira NL. Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. Br J Cancer. 2003; 89: 2027-2030.
  • 112
    Adams MP, Ahdieh H. Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. Pharmacotherapy. 2004; 24: 468-476.
  • 113
    Gabrail NY, Dvergsten C, Ahdieh H. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Curr Med Res Opin. 2004; 20: 911-918.
  • 114
    Sloan P. Review of oral oxymorphone in the management of pain. Ther Clin Risk Manag. 2008; 4: 777-787.
  • 115
    Sloan P, Slatkin N, Ahdieh H. Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study. Support Care Cancer. 2005; 13: 57-65.
  • 116
    Adams M, Pieniaszek HJ Jr, Gammaitoni AR, Ahdieh H. Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. J Clin Pharmacol. 2005; 45: 337-345.
  • 117
    Prommer E. Oxymorphone: a review. Support Care Cancer. 2006; 14: 109-115.
  • 118
    Wade WE, Spruill WJ. Tapentadol hydrochloride: a centrally acting oral analgesic. Clin Ther. 2009; 31: 2804-2818.
  • 119
    Prommer EE. Tapentadol: an initial analysis. J Opioid Manag. 2010; 6: 223-226.
  • 120
    Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004; 43: 879-923.
  • 121
    Rodriguez RF, Bravo LE, Castro F, et al. Incidence of weak opioids adverse events in the management of cancer pain: a double-blind comparative trial. J Palliat Med. 2007; 10: 56-60.
  • 122
    Kaiko RF, Foley KM, Grabinski PY, et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol. 1983; 13: 180-185.
  • 123
    Hawley PH, Byeon JJ. A comparison of sennosides-based bowel protocols with and without docusate in hospitalized patients with cancer. J Palliat Med. 2008; 11: 575-581.
  • 124
    Portenoy RK, Thomas J, Moehl Boatwright ML, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage. 2008; 35: 458-468.
  • 125
    Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008; 358: 2332-2343.
  • 126
    Bruera E, Driver L, Barnes EA, et al. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol. 2003; 21: 4439-4443.
  • 127
    Morita T, Tsunoda J, Inoue S, Chihara S. Effects of high dose opioids and sedatives on survival in terminally ill cancer patients. J Pain Symptom Manage. 2001; 21: 282-289.
  • 128
    Sykes N, Thorns A. Sedative use in the last week of life and the implications for end-of-life decision making. Arch Intern Med. 2003; 163: 341-344.
  • 129
    Sykes N, Thorns A. The use of opioids and sedatives at the end of life. Lancet Oncol. 2003; 4: 312-318.
  • 130
    Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010; 150: 573-581.
  • 131
    Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;( 4): CD005454.
  • 132
    Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007; 132: 237-251.
  • 133
    Durand JP, Goldwasser F. Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxine. Anticancer Drugs. 2002; 13: 777-780.
  • 134
    Tasmuth T, Hartel B, Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain. 2002; 6: 17-24.
  • 135
    Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007; 101: 113-121.
  • 136
    Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs. 2008; 22: 27-47.
  • 137
    Baron R, Brunnmuller U, Brasser M, May M, Binder A. Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: open-label, non-comparative, flexible-dose study. Eur J Pain. 2008; 12: 850-858.
  • 138
    Bennett MI. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review [published online ahead of print July 29, 2010]. Palliat Med.
  • 139
    Bar Ad V, Weinstein G, Dutta PR, et al. Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. Cancer. 2010; 116: 4206-4213.
  • 140
    Wooldridge JE, Anderson CM, Perry MC. Corticosteroids in advanced cancer. Oncology (Williston Park). 2001; 15: 225-234; discussion 234-236.
  • 141
    Shim K, MacKenzie MJ, Winquist E. Chemotherapy-associated osteonecrosis in cancer patients with solid tumours: a systematic review. Drug Saf. 2008; 31: 359-371.
  • 142
    Ferrini R, Paice JA. How to initiate and monitor infusional lidocaine for severe and/or neuropathic pain. J Support Oncol. 2004; 2: 90-94.
  • 143
    Fleming JA, O'Connor BD. Use of lidocaine patches for neuropathic pain in a comprehensive cancer centre. Pain Res Manag. 2009; 14: 381-388.
  • 144
    Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol. 2003; 43: 111-117.
  • 145
    Deer TR, Caraway DL, Kim CK, Dempsey CD, Stewart CD, McNeil KF. Clinical experience with intrathecal bupivacaine in combination with opioid for the treatment of chronic pain related to failed back surgery syndrome and metastatic cancer pain of the spine. Spine J. 2002; 2: 274-278.
  • 146
    Bell R, Eccleston C, Kalso E. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev. 2003;( 1): CD003351.
  • 147
    Mercadante S, Arcuri E, Tirelli W, Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage. 2000; 20: 246-252.
  • 148
    Finkel JC, Pestieau SR, Quezado ZM. Ketamine as an adjuvant for treatment of cancer pain in children and adolescents. J Pain. 2007; 8: 515-521.
  • 149
    Walker K, Medhurst SJ, Kidd BL, et al. Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain. Pain. 2002; 100: 219-229.
  • 150
    Groff L, Zecca E, De Conno F, et al. The role of disodium pamidronate in the management of bone pain due to malignancy. Palliat Med. 2001; 15: 297-307.
  • 151
    Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000; 88: 1082-1090.
  • 152
    Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003; 21: 4277-4284.
  • 153
    Lipton A, Small E, Saad F, et al. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest. 2002; 20( suppl 2): 45-54.
  • 154
    Vogel CL, Yanagihara RH, Wood AJ, et al. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist. 2004; 9: 687-695.
  • 155
    Clemons M, Dranitsaris G, Ooi W, Cole DE. A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast Cancer Res Treat. 2008; 108: 79-85.
  • 156
    Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361: 756-765.
  • 157
    Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010; 28: 5132-5139.
  • 158
    Jagdev SP, Purohit P, Heatley S, Herling C, Coleman RE. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol. 2001; 12: 1433-1438.
  • 159
    King AE, Umland EM. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. Pharmacotherapy. 2008; 28: 667-677.
  • 160
    Martinez MJ, Roque M, Alonso-Coello P, Catala E, Garcia JL, Ferrandiz M. Calcitonin for metastatic bone pain. Cochrane Database Syst Rev. 2003;( 3): CD003223.
  • 161
    Ellison N, Loprinzi CL, Kugler J, et al. Phase III placebo-controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients. J Clin Oncol. 1997; 15: 2974-2980.
  • 162
    Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 2008; 7: 1106-1112.
  • 163
    Simpson DM, Brown S, Tobias J. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology. 2008; 70: 2305-2313.
  • 164
    Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson TR. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin. 2007; 23: 17-24.
  • 165
    Rahn EJ, Zvonok AM, Thakur GA, Khanolkar AD, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther. 2008; 327: 584-591.
  • 166
    Ashton JC, Milligan ED. Cannabinoids for the treatment of neuropathic pain: clinical evidence. Curr Opin Investig Drugs. 2008; 9: 65-75.
  • 167
    Wang T, Collet JP, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. CMAJ. 2008; 178: 1669-1678.
  • 168
    Culleton S, Kwok S, Chow E. Radiotherapy for pain [published online ahead of print December 17, 2010]. Clin Oncol (R Coll Radiol).
  • 169
    Swetz KM, Smith TJ. Palliative chemotherapy: when is it worth it and when is it not? Cancer J. 2010; 16: 467-472.
  • 170
    Coyle N, Adelhardt J, Foley KM, Portenoy RK. Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. J Pain Symptom Manage. 1990; 5: 83-93.
  • 171
    Paice JA, Von Roenn JH, Hudgins JC, Luong L, Krejcie TC, Avram MJ. Morphine bioavailability from a topical gel formulation in volunteers. J Pain Symptom Manage. 2008; 35: 314-320.
  • 172
    Weinberg DS, Inturrisi CE, Reidenberg B, et al. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther. 1988; 44: 335-342.
  • 173
    Zeppetella G. Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study. Palliat Med. 2001; 15: 323-328.
  • 174
    Cerchietti LC, Navigante AH, Korte MW, et al. Potential utility of the peripheral analgesic properties of morphine in stomatitis-related pain: a pilot study. Pain. 2003; 105: 265-273.
  • 175
    Gourlay GK. Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine. Clin Pharmacokinet. 1998; 35: 173-190.
  • 176
    Hanks GW, Nugent M, Higgs CM, Busch MA. Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study. Palliat Med. 2004; 18: 698-704.
  • 177
    Rauck R, North J, Gever LN, Tagarro I, Finn AL. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol. 2010; 21: 1308-1314.
  • 178
    Taylor DR. Fentanyl buccal tablet: rapid relief from breakthrough pain. Expert Opin Pharmacother. 2007; 8: 3043-3051.
  • 179
    Vasisht N, Gever LN, Tagarro I, Finn AL. Single-dose pharmacokinetics of fentanyl buccal soluble film. Pain Med. 2010; 11: 1017-1023.
  • 180
    Fitzgibbon D, Morgan D, Dockter D, Barry C, Kharasch ED. Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients. Pain. 2003; 106: 309-315.
  • 181
    Rudy AC, Coda BA, Archer SM, Wermeling DP. A multiple-dose phase I study of intranasal hydromorphone hydrochloride in healthy volunteers. Anesth Analg. 2004; 99: 1379-1386; table of contents.
  • 182
    Nelson KA, Glare PA, Walsh D, Groh ES. A prospective, within-patient, crossover study of continuous intravenous and subcutaneous morphine for chronic cancer pain. J Pain Symptom Manage. 1997; 13: 262-267.
  • 183
    Parsons HA, Shukkoor A, Quan H, et al. Intermittent subcutaneous opioids for the management of cancer pain. J Palliat Med. 2008; 11: 1319-1324.
  • 184
    Anderson SL, Shreve ST. Continuous subcutaneous infusion of opiates at end-of-life. Ann Pharmacother. 2004; 38: 1015-1023.
  • 185
    Baker L, Lee M, Regnard C, Crack L, Callin S. Evolving spinal analgesia practice in palliative care. Palliat Med. 2004; 18: 507-515.
  • 186
    Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002; 20: 4040-4049.
  • 187
    Myers J, Chan V, Jarvis V, Walker-Dilks C. Intraspinal techniques for pain management in cancer patients: a systematic review. Support Care Cancer. 2010; 18: 137-149.
  • 188
    Vernassiere C, Cornet C, Trechot P, et al. Study to determine the efficacy of topical morphine on painful chronic skin ulcers. J Wound Care. 2005; 14: 289-293.
  • 189
    Ribeiro MD, Joel SP, Zeppetella G. The bioavailability of morphine applied topically to cutaneous ulcers. J Pain Symptom Manage. 2004; 27: 434-439.
  • 190
    Muijsers RB, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs. 2001; 61: 2289-2307.
  • 191
    Tassinari D, Sartori S, Tamburini E, et al. Transdermal fentanyl as a front-line approach to moderate-severe pain: a meta-analysis of randomized clinical trials. J Palliat Care. 2009; 25: 172-180.
  • 192
    Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain. 2009; 13: 219-230.
  • 193
    Vissers KC, Besse K, Hans G, Devulder J, Morlion B. Opioid rotation in the management of chronic pain: where is the evidence? Pain Pract. 2010; 10: 85-93.
  • 194
    The Partnership for a Drug-Free America. Not In My House: Reducing Teen Prescription Drug Abuse: Tips for Parents 2010. Available at: http://notinmyhouse.drugfree.org/steps.aspx#monitor. Accessed February 23, 2011.
  • 195
    American Pain Foundation. PainSAFE: Safety Tools & Resources. 2010. Available at: http://www.painfoundation.org/painsafe/safety-tools-resources. Accessed February 23, 2011.
  • 196
    Brogan S, Junkins S. Interventional therapies for the management of cancer pain. J Support Oncol. 2010; 8: 52-59.
  • 197
    Chambers WA. Nerve blocks in palliative care. Br J Anaesth. 2008; 101: 95-100.
  • 198
    Goetz MP, Callstrom MR, Charboneau JW, et al. Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol. 2004; 22: 300-306.
  • 199
    Wong GY, Schroeder DR, Carns PE, et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA. 2004; 291: 1092-1099.
  • 200
    Zhang CL, Zhang TJ, Guo YN, et al. Effect of neurolytic celiac plexus block guided by computerized tomography on pancreatic cancer pain. Dig Dis Sci. 2008; 53: 856-860.
  • 201
    Gofeld M, Bhatia A, Burton AW. Vertebroplasty in the management of painful bony metastases. Curr Pain Headache Rep. 2009; 13: 288-294.
  • 202
    Dupuy DE, Liu D, Hartfeil D, et al. Percutaneous radiofrequency ablation of painful osseous metastases: a multicenter American College of Radiology Imaging Network trial. Cancer. 2010; 116: 989-997.
  • 203
    Cata JP, Cordella JV, Burton AW, Hassenbusch SJ, Weng HR, Dougherty PM. Spinal cord stimulation relieves chemotherapy-induced pain: a clinical case report. J Pain Symptom Manage. 2004; 27: 72-78.
  • 204
    Stubblefield MD, Levine A, Custodio CM, Fitzpatrick T. The role of botulinum toxin type A in the radiation fibrosis syndrome: a preliminary report. Arch Phys Med Rehabil. 2008; 89: 417-421.
  • 205
    Bloch R. Rehabilitation medicine approach to cancer pain. Cancer Invest. 2004; 22: 944-948.
  • 206
    Raphael J, Hester J, Ahmedzai S, et al. Cancer pain: part 2: physical, interventional and complimentary therapies; management in the community; acute, treatment-related and complex cancer pain: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. Pain Med. 2010; 11: 872-896.
  • 207
    Cormier JN, Askew RL, Mungovan KS, Xing Y, Ross MI, Armer JM. Lymphedema beyond breast cancer: a systematic review and meta-analysis of cancer-related secondary lymphedema. Cancer. 2010; 116: 5138-5149.
  • 208
    Sagen A, Karesen R, Risberg MA. Physical activity for the affected limb and arm lymphedema after breast cancer surgery. A prospective, randomized controlled trial with two years follow-up. Acta Oncol. 2009; 48: 1102-1110.
  • 209
    Cassileth BR, Keefe FJ. Integrative and behavioral approaches to the treatment of cancer-related neuropathic pain. Oncologist. 2010; 15( suppl 2): 19-23.
  • 210
    Keefe FJ, Abernethy AP, C Campbell L. Psychological approaches to understanding and treating disease-related pain. Annu Rev Psychol. 2005; 56: 601-630.
  • 211
    Montgomery GH, Weltz CR, Seltz M, Bovbjerg DH. Brief presurgery hypnosis reduces distress and pain in excisional breast biopsy patients. Int J Clin Exp Hypn. 2002; 50: 17-32.
  • 212
    Chochinov HM, Breitbart W. Handbook of Psychiatry in Palliative Medicine. New York, NY: Oxford University Press; 2009.
  • 213
    Hadjistavropoulos T, Herr K, Turk DC, et al. An interdisciplinary expert consensus statement on assessment of pain in older persons. Clin J Pain. 2007; 23( 1 suppl): S1-S43.
  • 214
    Herr K, Bjoro K, Decker S. Tools for assessment of pain in nonverbal older adults with dementia: a state-of-the-science review. J Pain Symptom Manage. 2006; 31: 170-192.
  • 215
    Derby S, O'Mahony S, Tickoo R. Elderly patients. In: FerrellBR, CoyleN, eds. Oxford Textbook of Palliative Nursing. 3rd ed. New York, NY: Oxford University Press; 2010: 713-744.
  • 216
    Kok M, Portenoy RK. Cancer pain syndromes. In: BrueraE, PortenoyRK, eds. Cancer Pain. 2nd ed. New York, NY: Cambridge University Press; 2010: 37-52.
  • 217
    Levy MH, Chwistek M, Mehta RS. Management of chronic pain in cancer survivors. Cancer J. 2008; 14: 401-409.
  • 218
    Baxter NN, Habermann EB, Tepper JE, Durham SB, Virnig BA. Risk of pelvic fractures in older women following pelvic irradiation. JAMA. 2005; 294: 2587-2593.
  • 219
    Dropcho EJ. Neurotoxicity of radiation therapy. Neurol Clin. 2010; 28: 217-234.
  • 220
    Jaeckle KA. Neurologic manifestations of neoplastic and radiation-induced plexopathies. Semin Neurol. 2010; 30: 254-262.
  • 221
    Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008; 44: 1507-1515.
  • 222
    Cata JP, Weng HR, Burton AW, Villareal H, Giralt S, Dougherty PM. Quantitative sensory findings in patients with bortezomib-induced pain. J Pain. 2007; 8: 296-306.
  • 223
    Gutierrez-Gutierrez G, Sereno M, Miralles A, Casado-Saenz E, Gutierrez-Rivas E. Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clin Transl Oncol. 2010; 12: 81-91.
  • 224
    Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006; 33: 15-49.
  • 225
    Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006; 24: 3113-3120.
  • 226
    Bakitas MA. Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res. 2007; 56: 323-331.
  • 227
    Closs SJ, Staples V, Reid I, Bennett MI, Briggs M. Managing the symptoms of neuropathic pain: an exploration of patients' experiences. J Pain Symptom Manage. 2007; 34: 422-433.
  • 228
    Sun V, Otis-Green S, Shibata S, Lim D, Uman G, Ferrell B. Symptom Concerns and QOL in Oxaliplatin-Induced Peripheral Neuropathy. Paper presented at: 2008 Gastrointestinal Cancer Symposium; January 25-27, 2008; Orlando, FL. Abstract 503.
  • 229
    Burstein HJ, Winer EP. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol. 2007; 25: 3797-3799.
  • 230
    Felson DT, Cummings SR. Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum. 2005; 52: 2594-2598.
  • 231
    Henry NL, Giles JT, Ang D, et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat. 2008; 111: 365-372.
  • 232
    Mao JJ, Stricker C, Bruner D, et al. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer. 2009; 115: 3631-3639.
  • 233
    Sestak I, Cuzick J, Sapunar F, et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol. 2008; 9: 866-872.
  • 234
    Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007; 25: 3877-3883.
  • 235
    Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008; 26: 556-562.
  • 236
    Coleman RE, Bolten WW, Lansdown M, et al. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev. 2008; 34: 275-282.
  • 237
    Crew KD, Capodice JL, Greenlee H, et al. Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol. 2010; 28: 1154-1160.
  • 238
    Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol. 2001; 19: 3685-3691.
  • 239
    Friedrichs B, Tichelli A, Bacigalupo A, et al. Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol. 2010; 11: 331-338.
  • 240
    Fimiani M, De Aloe G, Cuccia A. Chronic graft versus host disease and skin. J Eur Acad Dermatol Venereol. 2003; 17: 512-517.
  • 241
    Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood. 2002; 100: 415-419.
  • 242
    Centers for Disease Control and Prevention. FastStats: Illegal Drug Use. Atlanta, GA: Centers for Disease Control and Prevention; 2010. Available at: http://www.cdc.gov/nchs/fastats/druguse.htm. Accessed February 23, 2011.
  • 243
    Department of Health and Human Services. SAMHSA's Latest National Survey on Drug Use and Health. Washington, DC: Department of Health and Human Services; 2010. Available at: http://oas.samhsa.gov/NSDUHLatest.htm. Accessed February 23, 2011.
  • 244
    Ballantyne JC. Opioid misuse in oncology pain patients. Curr Pain Headache Rep. 2007; 11: 276-282.
  • 245
    Kirsh KL, Passik SD. Palliative care of the terminally ill drug addict. Cancer Invest. 2006; 24: 425-431.
  • 246
    Passik S, Kirsh KL, Portenoy RK. Pain and addictive disease. In: Von RoennJH, PaiceJA, PreodorM, eds. Current Diagnosis and Treatment of Pain. New York, NY: Lange Medical Books; 2006: 79.
  • 247
    Webster LR, Fine PG. Approaches to improve pain relief while minimizing opioid abuse liability. J Pain. 2010; 11: 602-611.
  • 248
    Cone EJ, Caplan YH. Urine toxicology testing in chronic pain management. Postgrad Med. 2009; 121: 91-102.
  • 249
    Pillet S, Eschiti V. Managing chronic pain in patients with cancer who have a history of substance abuse. Clin J Oncol Nurs. 2008; 12: 663-667.
  • 250
    Paice JA. Pain at the end of life. In: FerrellBR, CoyleN, eds. Oxford Textbook of Palliative Nursing. 3rd ed. New York, NY: Oxford University Press; 2010: 161-185.